Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
Patients must have received prior therapy other than surgery and must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required timeframe, the defined eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately
Prior cancer treatment must be completed at least 28 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to =< grade 1 or baseline
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
Has recovered from the toxic effects of prior therapy to their clinical baseline
Subjects must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
Patient must have recovered from any toxic effects of previous chemotherapy, targeted therapy or radiotherapy as judged by the investigator to ? grade 1
Be fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy. Residual chronic toxicities of prior therapy ? grade 2 (eg, peripheral neuropathy, residual alopecia) are allowed.
Recovered from the toxic effects of prior therapy to < grade 2 toxicity per NCI CTCAE prior to study registration (except lymphopenia).
TREATMENT INCLUSION: Recovered from all acute non-hematologic toxic effects of all prior chemotherapy
Has not recovered to Grade ?1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy. Note: Subjects with Grade ?2 neuropathy is an exception and may enroll.
Prior Therapy- Patients must have fully recovered from the acute toxic effects of all prior anti- cancer chemotherapy and be within the following timelines:
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Has recovered from the toxic effects of prior therapy to their clinical baseline
INCLUSION - TREATMENT: Recovered from the acute toxic effects of all prior chemotherapy
Participants must have fully recovered from the acute toxic effects of all prior treatment to grade 1 or less, except alopecia and =< grade 2 neuropathy which are allowed
Patients who relapse on therapy other than standard ALL maintenance must have fully recovered from the acute toxic effects of all prior anti-cancer therapy, defined as resolution of all such toxicities to ? grade 2 or lower per the inclusion/exclusion criteria prior to entering this study
Patients must have recovered to =< grade 1 or stabilized from the toxic effects of any prior chemotherapy (except alopecia)
Prior cancer treatment (systemic therapy or radiation therapy) must be completed at least 3 weeks prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to grade =< 1 or baseline.
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Patient must have recovered from acute toxic effects (? grade 1) of previous cancer treatments prior to enrollment
Participants must have fully recovered from the acute toxic effects of all prior anticancer therapies or must adhere to post-treatment conditions as follows:
Recovered from all acute side-effects (except alopecia) related to previous systemic therapy
No chemotherapy, radiation, or major surgery within two weeks prior to first dose of study drug and/or recovered from the toxic side effects of that therapy, unless treatment is indicated due to progressive disease.
Recovered to Grade 1 or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).
Participants must have fully recovered from the acute toxic effects of all prior anticancer treatments prior to study drug administration:
Patients must have recovered from the toxic effects of prior therapy at the time of initiation of the study drug unless toxicity is stable
Patient must have recovered from the acute toxic effects (? grade 1 CTCAE v.4.0) of previous anti-cancer treatment prior to study enrollment; the only exception is that grade 2 neuropathy is permitted
Prior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ?grade 1 or to baseline prior to initiation of that therapy.
Participants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
Patients who have not recovered from the toxic effects of prior chemo- and/or radiation therapy; guidelines for this recovery period are dependent upon the specific therapeutic agent being used
Patients must have recovered from the acute toxic effects of all prior therapy to =< grade 1 before entering this study
Radiation therapy (within 12 weeks of Study Day 1 or has not recovered from the toxic effects of such therapy).
GliadelÂ® Wafer (within 6 months of Study Day 1, or has not recovered from the toxic effects of such therapy).
Immunotherapeutic agents, vaccines, or monoclonal antibody therapy (within 4 weeks of Study Day 1 or has not recovered from the toxic effects of such cancer therapy).
Temozolomide or other chemotherapy (within 4 weeks of Study Day 1 or 6 weeks for nitrogen mustards, or has not recovered from the toxic effects of such cancer therapy).
Surgical resection of brain tumor (within 4 weeks of Study Day 1 or has not recovered from acute side effects of such therapy except for neurological effects).
Must have recovered from the acute toxic effects of all prior therapy prior to registration for this study to grade 1 or less
Subjects must have recovered from the toxic effects of any prior chemotherapy to < grade 1 (except alopecia)
Treated with immunotherapeutic agents, vaccines, or monoclonal antibody (Mab) therapy within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Treated with alkylating agents within 4 weeks (6 weeks for nitrosoureas) before enrollment or treated within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy to their baseline or to grade 1
Prior treatment (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Must have recovered from the toxic effects of all prior chemotherapy
Patients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy, including standard and investigational treatments for AA, for at least 1 week or 5 half-lives whichever comes later, prior to entering this study, and have recovered from the toxic effects of that therapy to Grade 1 or less.
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy or radiation to grade 2 or less
At the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade 1 toxicity
Patients must have recovered (to Common Toxicity Criteria [CTC] version [v.]4.0 =< grade 1 unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy prior to entering this study, with the exception of alopecia, weight changes and grade I or II lymphopenia
Must have recovered from toxic effects of prior chemotherapy
Treated with immunotherapeutic agents within 4 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Treated with alkylating agents within 4 weeks before enrollment (6 weeks for nitrosoureas) or treated within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy
Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unless the patient has recovered from the expected toxic effects of such therapy
Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy
Patients must have recovered from the toxic effects of prior therapy
Prior Therapy- Patients must have fully recovered from the acute toxic effects of all prior anti- cancer chemotherapy and be within the following timelines:
Patients must have recovered from the toxic effects of any prior chemotherapy to < grade 2 (except for alopecia)
Patients who have not recovered from side effects of prior anti-cancer treatment to less than or equal to grade 1 toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 within the following time frames:\r\n* Received previous systemic therapy and has not recovered from side effects for more than 14 days prior to starting on treatment\r\n* Received previous radiation therapy and has not recovered from side effects for more than 14 days prior to starting on treatment\r\n* Received previous biologic therapy and has not recovered from side effects for more than 14 days prior to starting on treatment
No acute toxic effects from previous treatment superior to grade 1 at the start of the study
Prior radiation therapy is permitted as long as:\r\n* Recovered from the toxic effects of radiation treatment before study entry, except for alopecia
Patients must have been off of cytotoxic, immunosuppressive (except steroids), or targeted therapy for at least 2 weeks prior to entering this study, and have recovered from the toxic effects of that therapy to grade 1 or less
Has not recovered from toxic effect of prior therapy to < Grade 1.
Participants must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to study drug administration. If, after the required time frame, the numerical eligibility criteria are met, eg, blood count criteria, the participant is considered to have recovered adequately:
Have recovered from the acute effects of any prior systemic therapy.
Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent
Patients must have been off chemotherapy for 2 weeks prior to entering this study unless there is evidence of rapidly progressive disease. Patients must have recovered from the toxic effects of prior therapy to grade ?1. The use of hydroxyurea is allowed to control counts up to 24 hrs prior to the start of therapy with AR-67.
No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of study drug and recovered from toxic side effects of that therapy, unless treatment is indicated due to progressive disease.
Has not recovered to ? Grade 1 or baseline from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study treatment.
Patients must have recovered from side effects resulting from prior cancer-directed therapy to a level of grade 1 or less (unless deemed not clinically significant by study investigator)
Subjects that have not recovered from side effects of previous therapy.
Participants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
Subjects must have recovered from the toxic effects of any prior chemotherapy to =< grade 1 (except alopecia)
Patients must have recovered from the toxic effects of prior therapies (=< grade 1)
Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g., grade 1 peripheral neuropathy, and residual alopecia are allowed)
Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy - residual grade 1 toxicity, e.g., grade 1 peripheral neuropathy and residual alopecia are allowed
Patients who have not recovered to grade =< 1 or to their baseline from clinically significant adverse effects
Recovered from the toxic effects of all prior chemotherapy
Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion
Subjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.
Patient must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer
Has not recovered to ? Grade 1 from toxic effects of prior therapy.
Has not recovered from toxic effects of prior therapy to ? Grade 1.
Recovery from the toxic effects of prior therapy, with a minimum time of:
Patient must have recovered from the acute toxic effects of the treatment before beginning study therapy.
Previous radiation therapy was allowed but must have been discontinued at least 2 months before study drug is administered, and the patient must have recovered from acute toxic effects
Radiation therapy completed at least 7 days prior to start of study treatment and patients must have recovered from any acute adverse effects.
Patients must have recovered from the toxic effects of prior therapies
Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g. grade 1 peripheral neuropathy, and residual alopecia are allowed)
Subjects must have recovered from the toxic effects of prior therapy; residual toxicity from any previous treatment must be =< Grade 1
Has not recovered to ? Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.
Recovered from toxic effects attributed to UC-961 to grade 1 levels, or baseline
Participant has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.
Patients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator)
Treatment with any investigational agent within 28 days prior to registration for protocol therapy and the subject must have recovered from the acute toxic effects of the regimen.
Participants must have recovered to grade 0 or 1 or pre-treatment baseline from clinically significant toxic effects of prior therapy (including but not limited to exceptions of alopecia, laboratory values listed per inclusion criteria, and lymphopenia which is common after therapy with temozolomide)
History of prior malignancy, except for conditions as listed in the protocol if patients have recovered from the acute side effects incurred as a result of previous therapy
Subjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (For example, subjects with residual Grade 1 toxicity or stable Grade 2 peripheral neuropathy due to prior chemotherapy are allowed with approval of the Medical Monitor.)
Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy (toxicity < grade 2)
The patient has not recovered from the acute toxic effects of prior chemotherapy, radiation, or major surgery/significant trauma.
Participants must have fully recovered from the acute toxic effects of all prior anti-cancer therapy
Subjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor.)
At the time of registration, patient must have recovered from the toxic effects of prior therapy to no more than grade 1 toxicity
No acute toxic effects from previous treatment superior to grade 1 at the start of the study
Patients must have recovered from the toxic effects of all prior therapy before entering this study
Patients must have been off chemotherapy for 2 weeks prior to entering this study, unless there is evidence of rapidly progressive disease, and must have recovered from the toxic effects of that therapy to at least grade 1. Use of hydroxyurea for patients with rapidly proliferative disease is allowed before the start of study therapy and for the first four weeks on therapy.
Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiation therapy prior to entry on study; patients must have had at least one prior treatment regimen; patients may have received treatment previously with cyclophosphamide topotecan or bevacizumab
Patients may be treated on this trial without having received prior therapy; if patients have received prior therapy, they must have recovered from all toxic effects prior to entering this study
Recovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ? 1 or to the baseline laboratory values.
Prior therapy: \r\n* The patientâs malignancy must have relapsed after or failed to respond to frontline curative therapy and/or there must not be any potentially curative treatment options available at the time of study entry\r\n* There is no limit to the number of prior treatment regimens; however, patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment; acute toxicity of any previous therapy must have resolved to grade 1 or less, unless specified elsewhere
Participants must have fully recovered from the acute toxic effects of all prior therapy prior to first administration of study drug
Has not recovered from toxic effect of prior therapy to < Grade 1.
Patients must have recovered from side effects from prior cancer-directed therapy to grade 1 or less (unless deemed not clinically significant by study investigator)
Patient has not recovered from the acute toxic effects of prior anticancer therapy, radiation, or major surgery/significant trauma.
Use of an investigational agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade 0 or 1 (except alopecia and neuropathy).
Have discontinued previous treatments for cancer and recovered from all acute toxic effects of prior systemic therapy (except alopecia) to grade ?1;
Recovery from the toxic effects of prior therapy to not more than grade 1 or > 3 weeks from prior therapy to registration, whichever is later
Has not recovered to ? Grade 1 from toxic effects of prior therapy.
Patients must have been off all prior therapy for leukemia except hydroxyurea for 1 week prior to entering this study and recovered from the toxic effects of that therapy
Prior/Concurrent Therapy: Research participants must have recovered from the acute effects of prior treatment and:
Patients must have recovered from the toxic effects of prior therapy at the time of registration as follows:
Patient has recovered from the toxic effects of prior therapy, and is at least 30 days from the most recent cytotoxic therapy, prior to enrollment
At the time of registration, subjects must have recovered from the toxic effects of previous treatments, as determined by the treating physician.
Patients who have received prior adjuvant high dose interferon are allowed to participate as long as the last injection was given at least 30 days prior to the C11-AMT PET scan and they have fully recovered from side effects (i.e., grade =< 1 or permanent side effects that require hormone replacement therapy)
Prior therapy: Must have recovered from acute toxic effects of prior anti-cancer therapy (durations relative to date of enrollment):
Pregnant or breastfeeding (due to toxic effects from tobacco products).
Has not recovered to ? Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.
Has not recovered to ? Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy
